Overall, 5–10% of breast cancers are attributed to the inheritance of a mutation in the tumor suppressor BRCA1 gene (BRCA1m).5 Yet, up to 70–90% of BRCA1m carriers develop TNBC.6 There are variable forms of BRCA1m, which increases the difficulty of potentially targeting those specific mutations for TNBC therapy. Here, BRCA1 is linked to breast carcinoma.